Clinical Trials
33 trialsToripalimab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer
Peking Union Medical College Hospital
HAI-TL
Eastern Hepatobiliary Surgery Hospital
Efficacy and Biomarker Explanation of IBI-322 Plus Lenvatinib on Extensive Stage Small Cell Lung Cancer
Hunan Province Tumor Hospital
CCGLC-012
Tongji Hospital
Pucotenlimab Combined With Lenvatinib as a Neodjuvant Therapy for Non Clear Cell Renal Cell Carcinoma
Sun Yat-sen University
OPTIONS-05
Fudan University
CASTLE-09
Fudan University
CASTLE-10
Fudan University
Icaritin Soft Capsule Combined With Lenvatinib and TACE for the Treatment of Hepatocellular Carcinoma
Zhejiang Cancer Hospital
Toripalimab Plus Lenvatinib as Second-line Treatment in Advanced Biliary Tract Cancers
Peking Union Medical College Hospital
Lenvatinib Combined Toripalimab in Advanced Hepatocellular Carcinoma
Peking Union Medical College Hospital
CASTLE-08
Fudan University
Durvalumab Plus Lenvatinib as First-line Treatment for Unresectable Hepatocellular Carcinoma
Zhejiang University
Cryoablation Combined With Tislelizumab Plus Lenvatinib in Patients With Melanoma Liver Metastasis
Fudan University
Envofolimab and Lenvatinib Combined With Gemcitabine Plus Cisplatin for Advanced BTC as First-Line Treatment(ENLIGHTEN)
Sun Yat-sen University
TACE Combined With Lenvatinib and MWA in the Treatment of Locally Advanced Large Hepatocellular Carcinoma
Sun Yat-sen University
LEADER-001
The First Hospital of Jilin University
Tislelizumab+Lenvatinib+Gemox Regiment for Potentially Resectable Locally Advanced Malignant Tumors of Biliary System.
Tianjin Medical University Cancer Institute and Hospital
Envafolimab, Lenvatinib Combined With VP-16 in Platinum-resistant Recurrent Epithelial Ovarian Cancer
Zhongda Hospital
LENVOS
Centre Leon Berard
Tisleizumab Combined With Lenvatinib and XELOX Regimen (Oxaliplatin Combined With Capecitabine) in the First-line Treatment of Advanced and Unresectable Biliary Tract Tumors
The First Affiliated Hospital with Nanjing Medical University
Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLC
The University of Hong Kong
Trial of Lenvatinib Plus PembrolizumAb in Recurrent Gynecological Clear Cell Adenocarcinomas (LARA)
National University Hospital, Singapore
TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma
Shanghai Zhongshan Hospital
PLATIC
Sun Yat-sen University
Combined Therapy Using Oxaliplatin and Gemcitabine Chemotherapy, Lenvatinib and PD1 Antibody (JS001) for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma
Shanghai Zhongshan Hospital
Sintilimab Combined With Lenvatinib in Local Advanced Hepatocellular Carcinoma
Peking University Cancer Hospital & Institute
Systemic Chemotherapy Plus Lenvatinib and Toripalimab for HCC With Extrahepatic Metastasis
Sun Yat-sen University
Study of HX008 in Combination With Bevacizumab or Lenvatinib for the Treatment of Advanced Hepatocellular Carcinoma (HCC)
Taizhou Hanzhong biomedical co. LTD
PLTHCC
Tianjin Medical University Cancer Institute and Hospital
Efficacy and Safety of Lenvatinib as a Conversion Therapy for HCC
Shanghai Zhongshan Hospital
Efficacy and Safety of Lenvatinib as an Adjuvant Therapy for Hepatocellular Carcinoma
Shanghai Zhongshan Hospital
Phase II Study of Single Agent Lenvatinib
National University Hospital, Singapore